TY - STD TI - Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; ID - ref1 ER - TY - JOUR AU - Hernandez, A. V. PY - 2006 DA - 2006// TI - Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? JO - Am Heart J VL - 151 UR - https://doi.org/10.1016/j.ahj.2005.04.020 DO - 10.1016/j.ahj.2005.04.020 ID - Hernandez2006 ER - TY - CHAP AU - Guyatt, G. AU - Wyer, P. C. AU - Ioannidis, J. ED - Guyatt, G. PY - 2008 DA - 2008// TI - When to believe a subgroup analysis BT - User’s guide to the medical literature: a manual for evidence-based clinical practice ID - Guyatt2008 ER - TY - JOUR AU - Sun, X. PY - 2011 DA - 2011// TI - The influence of study characteristics on reporting of subgroup analyses in randomized controlled trials: systematic review JO - BMJ VL - 342 UR - https://doi.org/10.1136/bmj.d1569 DO - 10.1136/bmj.d1569 ID - Sun2011 ER - TY - STD TI - Sun X, co. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012;344:e1553. https://doi.org/10.1136/bmj.e1553. ID - ref5 ER - TY - JOUR AU - Heiat, A. AU - Gross, C. P. AU - Krumholz, H. M. PY - 2002 DA - 2002// TI - Representation of the elderly, women, and minorities in heart failure clinical trials JO - Arch Intern Med VL - 162 UR - https://doi.org/10.1001/archinte.162.15.1682 DO - 10.1001/archinte.162.15.1682 ID - Heiat2002 ER - TY - STD TI - Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016 Nov 1;316(17):1818–9. ID - ref7 ER - TY - STD TI - Varadhan R, et al. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol. 2013;66(8):818–25. https://doi.org/10.1016/j/jclinepi.2013.02.009. ID - ref8 ER - TY - JOUR AU - Pocock, S. J. AU - Hughes, M. D. AU - Lee, R. J. PY - 1987 DA - 1987// TI - Statistical problems in the reporting of clinical trials. A survey of three medical journals JO - N Engl J Med VL - 317 UR - https://doi.org/10.1056/NEJM198708133170706 DO - 10.1056/NEJM198708133170706 ID - Pocock1987 ER - TY - STD TI - Annals of Internal Medicine. http://annals.org/ UR - http://annals.org/ ID - ref10 ER - TY - STD TI - The BMJ: leading general medical journal. Research. http://www.bmj.com/ UR - http://www.bmj.com/ ID - ref11 ER - TY - STD TI - The JAMA Network | Home of JAMA and the Specialty Journals of the American Medical Association. http://jama.jamanetwork.com/journal.aspx UR - http://jama.jamanetwork.com/journal.aspx ID - ref12 ER - TY - STD TI - The Lancet journal. http://www.thelancet.com/ UR - http://www.thelancet.com/ ID - ref13 ER - TY - STD TI - The New England Journal of Medicine: Research & Review Articles. http://www.nejm.org/k UR - http://www.nejm.org/ ID - ref14 ER - TY - STD TI - PLOS Medicine: A Peer-Reviewed Open-Access Journal. http://journals.plos.org/plosmedicine/ UR - http://journals.plos.org/plosmedicine/ ID - ref15 ER - TY - JOUR AU - Assmann, S. F. PY - 2000 DA - 2000// TI - Subgroup analysis and other (mis)uses of baseline data in clinical trials JO - Lancet. VL - 355 UR - https://doi.org/10.1016/S0140-6736(00)02039-0 DO - 10.1016/S0140-6736(00)02039-0 ID - Assmann2000 ER - TY - JOUR AU - Rothwell, P. M. PY - 2005 DA - 2005// TI - Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation JO - Lancet VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)17709-5 DO - 10.1016/S0140-6736(05)17709-5 ID - Rothwell2005 ER - TY - JOUR AU - Wang, R. PY - 2007 DA - 2007// TI - Statistics in medicine reporting of subgroup analyses in clinical trials JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMsr077003 DO - 10.1056/NEJMsr077003 ID - Wang2007 ER - TY - STD TI - Liberati A, co. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006. ID - ref19 ER - TY - JOUR AU - Gabler, N. PY - 2009 DA - 2009// TI - Dealing with heterogeneity of treatment effects: is the literature up to the challenge? JO - Trials. VL - 10 UR - https://doi.org/10.1186/1745-6215-10-43 DO - 10.1186/1745-6215-10-43 ID - Gabler2009 ER - TY - STD TI - Varadhan R. Johns Hopkins. In: Chapter 3. Estimation and reporting of heterogeneity of treatment effects. Developing an observational CER protocol: a user’s guide. ID - ref21 ER - TY - JOUR AU - Yusuf, S. AU - Wittes, J. PY - 1991 DA - 1991// TI - Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials JO - JAMA. VL - 266 UR - https://doi.org/10.1001/jama.1991.03470010097038 DO - 10.1001/jama.1991.03470010097038 ID - Yusuf1991 ER - TY - JOUR AU - Alatorre, C. I. PY - 2011 DA - 2011// TI - A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas. 2011 Blackwell publishing ltd JO - Int J Clin Pract VL - 65 UR - https://doi.org/10.1111/j.1742-1241.2011.02703.x DO - 10.1111/j.1742-1241.2011.02703.x ID - Alatorre2011 ER - TY - STD TI - Burke JF, et al. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;351:h5651. https://doi.org/10.1136/bmj.h5651. ID - ref24 ER - TY - JOUR AU - Altman, D. G. PY - 1996 DA - 1996// TI - Better reporting of randomized controlled trials: the CONSORT statement JO - BMJ VL - 313 UR - https://doi.org/10.1136/bmj.313.7057.570 DO - 10.1136/bmj.313.7057.570 ID - Altman1996 ER - TY - JOUR AU - Von Elm, E. PY - 2007 DA - 2007// TI - The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies JO - PLoS Med VL - 4 UR - https://doi.org/10.1371/journal.pmed.0040296 DO - 10.1371/journal.pmed.0040296 ID - Von Elm2007 ER - TY - STD TI - Rassen JA, et al. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012;21(7):697–709. https://doi.org/10.1002/pds.2256. Epub 2011 Dec 8 ID - ref27 ER - TY - JOUR AU - Perlis, R. H. PY - 2005 DA - 2005// TI - Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry JO - Am J Psychiatry VL - 162 UR - https://doi.org/10.1176/appi.ajp.162.10.1957 DO - 10.1176/appi.ajp.162.10.1957 ID - Perlis2005 ER - TY - STD TI - National Library of Medicine. Abridged index medicus (aim or “core clinical”) journal titles. 2015. www.nlm.nih.gov/bsd/aim.html. UR - http://www.nlm.nih.gov/bsd/aim.html ID - ref29 ER - TY - JOUR AU - Boutron, I. PY - 2010 DA - 2010// TI - Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes JO - JAMA VL - 303 UR - https://doi.org/10.1001/jama.2010.651 DO - 10.1001/jama.2010.651 ID - Boutron2010 ER - TY - JOUR AU - Rothman, K. J. AU - Greenland, S. AU - Walker, A. M. PY - 1980 DA - 1980// TI - Concepts of interaction JO - Am J Epidemiol VL - 112 UR - https://doi.org/10.1093/oxfordjournals.aje.a113015 DO - 10.1093/oxfordjournals.aje.a113015 ID - Rothman1980 ER - TY - JOUR AU - Sox, H. C. AU - Helfand, M. AU - Grimshaw, J. AU - Dickersin, K. PY - 2010 DA - 2010// TI - PLoS medicine editors, Tovey D, Knottnerus JA, Tugwell P. Comparative effectiveness research: challenges for medical journals JO - Am J Manag Care VL - 16 ID - Sox2010 ER - TY - JOUR AU - Brookes, S. T. PY - 2004 DA - 2004// TI - Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test JO - J Clin Epidemiol. VL - 57 UR - https://doi.org/10.1016/j.jclinepi.2003.08.009 DO - 10.1016/j.jclinepi.2003.08.009 ID - Brookes2004 ER - TY - JOUR AU - Rubin, D. B. PY - 2008 DA - 2008// TI - For objective causal inference, design trumps analysis JO - Ann Appl Stat VL - 2 UR - https://doi.org/10.1214/08-AOAS187 DO - 10.1214/08-AOAS187 ID - Rubin2008 ER - TY - STD TI - GA Wells, B Shea, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. UR - http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp ID - ref35 ER -